€0.025 jump Mar 2026: ViewRay (6L9.F XETRA) pre-market mover: liquidity watch

First trade action shows 6L9.F stock at €0.025 in XETRA pre-market on 31 Mar 2026 after a sharp volume pick-up. Volume is 3,500 versus a 50-day average of 279, a 12.54x relative jump. The move follows renewed listings and media coverage and has pushed the day high to €0.025 from an open of €0.001. For traders focused on high-volume movers, the combination of ultra-low price, outsized relative volume, and wide historical range requires tight risk controls.

Pre-market snapshot for 6L9.F stock

Price action at the open shows ViewRay, Inc. (6L9.F) trading at €0.025 on XETRA with a trading volume of 3,500 shares. Average volume sits at 279, so current activity is a clear high-volume signal.

Market microstructure: the day low printed €0.001 and day high €0.025, with a previous close of €0.001. Market cap is about €207,228,256.00 and shares outstanding are 8,289,130,240.00. These figures underline that small absolute moves produce large percentage swings.

Why volume spiked and recent 6L9.F news

Trading interest appears linked to renewed listings and coverage in market feeds, including a recent Reuters company page update for ViewRay (VRAYQ.PK) that brought the name back to screens. Heavy retail attention and low per-share price often create short-term liquidity surges.

Connectivity note: news flow alone does not equal fundamentals. The Reuters update is an informational trigger; traders are reacting to availability and momentum rather than fresh earnings data. See the Reuters listing for the latest company notices and quotes source.

Fundamentals and valuation for ViewRay (6L9.F)

ViewRay operates in the Healthcare sector, Medical – Devices industry, selling MRIdian MRI-guided radiation systems. Trailing metrics show EPS -0.55 and a negative PE. Key ratios: P/S 2.32, P/B 0.06, current ratio 2.36, and debt/equity 1.05.

These numbers indicate meaningful liquidity on the balance sheet with negative profitability. Revenue per share is 0.57 and cash per share is 0.75, but operating cash flow per share is negative -0.51, so cash runway and capital allocation matter for longer-term recovery.

Meyka grade, technicals and 6L9.F stock forecast

Meyka AI rates 6L9.F with a score out of 100. Meyka AI rates 6L9.F with a score out of 100 and assigns a score 61.25 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

Meyka AI’s forecast model projects a 12-month median base case of €0.10, a conservative bear case of €0.01, and a bull case of €0.25. At the current €0.025, the model implies a median upside of 300.00% to €0.10 and a downside of -60.00% to €0.01. Forecasts are model-based projections and not guarantees.

Catalysts, risks and sector context for 6L9.F stock

Catalysts: renewed listings, incremental media attention, new system orders for MRIdian, and any positive clinical adoption data could lift sentiment. Healthcare sector trends show moderate weakness YTD; medical devices require steady capital spending for recovery.

Risks: low absolute share price volatility, high dilution risk, negative operating margins, stretched receivables (DSO 147.79 days), and reliance on hospital capital budgets. Debt metrics and interest coverage are weak, increasing refinancing and liquidity risk if revenue growth stalls.

Trading strategy and practical steps for high-volume moves

For pre-market high-volume trades in 6L9.F stock, use limit orders, tight position sizing, and stop-losses given the tiny price base and potential for rapid reversals. Monitor real-time volume and the bid-ask spread; wide spreads can erase gains quickly.

Short-term traders may target the intraday range between €0.001 and €0.025, while longer-term investors should wait for sustained revenue improvement, margin recovery, and clearer guidance from management. See our Meyka stock page for live quotes and alerts Meyka ViewRay (6L9.F) page.

Final Thoughts

Key takeaway: 6L9.F stock is a pre-market high-volume mover on XETRA at €0.025 with outsized relative volume (3,500 vs 279 average). That spike reflects relisting coverage and short-term liquidity rather than new fundamentals. Meyka AI’s forecast model projects a 12-month median target of €0.10, implying a 300.00% upside from the current price, while a conservative bear scenario at €0.01 implies -60.00% downside. Meyka AI grade sits at 61.25 (B, HOLD), balancing recovery potential with ongoing profitability and liquidity risks. Traders should size positions for volatility, use limit orders, and watch real-time spreads. Forecasts are model-based projections and not guarantees; treat moves as high-risk trading events and consider sector momentum and company updates before adding exposure.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.